Efficacy and cardiovascular safety profile of dual bronchodilation therapy in chronic obstructive pulmonary disease: A bidimensional comparative analysis across fixed-dose combinations

Publication date: Available online 11 September 2019Source: Pulmonary Pharmacology & TherapeuticsAuthor(s): Paola Rogliani, Maria Gabriella Matera, Beatrice Ludovica Ritondo, Ilaria De Guido, Ermanno Puxeddu, Mario Cazzola, Luigino CalzettaAbstractDespite several long-acting β2-adrenoceptors agonist (LABA)/long-acting muscarinic antagonist (LAMA) fixed-dose combinations (FDCs) are currently approved in chronic obstructive pulmonary disease (COPD), there are limited findings concerning the direct comparison across the different LABA/LAMA FDCs. The aim of this study was to compare the efficacy/safety profile of approved LABA/LAMA FDCs in COPD. A network meta-analyses was performed by linking the efficacy (forced expiratory volume in 1 s, St’ George Respiratory Questionnaire, transitional dyspnea index) and safety (cardiovascular serious adverse events) outcomes resulting from randomized controlled trials that directly compared LABA/LAMA FDCs with placebo and/or each other. The Surface Under the Cumulative Ranking Curve Analysis (SUCRA) was performed for each single outcome (SUCRA: 1 = best, 0 = worst). The combined efficacy/safety profile was reported via the Improved Bidimensional SUCRA score (IBiS: the higher the value the better the treatment). Data obtained from 12,136 COPD patients (79.50% LABA/LAMA FDCs vs. placebo; 20.50% direct comparison between different LABA/LAMA FDCs) were extracted from 22 studies published between 2013 and 2019. The IBiS score showed ...
Source: Pulmonary Pharmacology and Therapeutics - Category: Respiratory Medicine Source Type: research